Clinical outcomes among morbidly obese patients hospitalized with diabetic foot complications.


Journal

Clinical obesity
ISSN: 1758-8111
Titre abrégé: Clin Obes
Pays: England
ID NLM: 101560587

Informations de publication

Date de publication:
02 2019
Historique:
received: 14 02 2018
revised: 15 08 2018
accepted: 26 08 2018
pubmed: 6 10 2018
medline: 19 3 2019
entrez: 6 10 2018
Statut: ppublish

Résumé

The aim of the study is to investigate effects of morbid obesity on patients hospitalized with diabetic foot ulcers and infections (DFU/Is). This retrospective cohort study of hospitalized adults investigated patients with a principal diagnosis of DFU/Is, and compared outcomes based on weight. The primary outcome was lower limb amputations. Secondary outcomes included in-hospital mortality, morbidity (sepsis and discharge disposition), resource utilization (length of stay [LOS] and total hospitalization charges). Multivariate analyses adjusted for confounders. A total of 31 730 admissions were included; 14% were morbidly obese. Patients with morbid obesity had overall lower rates of amputations (adjusted odds ratio [aOR]: 0.60; 95% confidence interval [CI]: 0.45-0.80). There was no difference in mortality rates between those who were morbidly obese and the non-morbidly obese patients (aOR: 3.89 [95% CI: 0.79-19.30]). Combined data from 2010 to 2014 have found higher odds of sepsis in morbidly obese patients compared with non-morbidly obese patients after adjusting for confounders (aOR: 1.49 [1.09-2.02], P = 0.01). Patients with morbid obesity were less likely to be discharged to home (aOR: 0.82 [95% CI: 0.70-0.95]), had longer LOS (adjusted mean difference [aMD]: 0.47 [95% CI: 0.13-0.81]) and higher hospital charges (aMD: $3205 [95% CI: $3373-$6037]). Despite having lower amputation rates compared to those who are not morbidly obese, patients with morbid obesity hospitalized for DFU/Is succumbed to sepsis more frequently and had less favourable utilization metrics. Specialized care pathways may be needed to enhance the value of care delivered to this high-risk population.

Identifiants

pubmed: 30288938
doi: 10.1111/cob.12285
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e12285

Subventions

Organisme : Johns Hopkins' Center for Innovative Medicine
Organisme : National Heart, Lung, and Blood Institute to the University of Mississippi Medical Center
ID : 1R25HL126145-01

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2018 World Obesity Federation.

Auteurs

Che Matthew Harris (CM)

Division of General Internal Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.

Marwan S Abougergi (MS)

Department on Internal Medicine, Division of Gastroenterology, University of South Carolina School of Medicine, Columbia, South Carolina, USA.
Catalyst Medical Consulting, Simpsonville, South Carolina, USA.

Scott Mitchell Wright (SM)

Division of General Internal Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH